Lucid Diagnostics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), will participate in two investor events: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026 and the Canaccord Genuity 46th Annual Growth Conference fireside chat on August 11, 2026 at 11:30 AM ET in Boston, MA. The Canaccord fireside chat will be available via live and archived webcast through the Investor Relations section of the Lucid Diagnostics website, with a replay accessible for 30 days after the live broadcast.

Market Reaction – PAVM

-4.00% $5.28

15m delay

-4.00% Vs previous close

$5.28 Last Price

$4.97 $5.75 Day Range

$37.80M Market Cap

0.3x Rel. Volume

Following this news, PAVM has declined 4.00%, reflecting a moderate negative market reaction. The stock is currently trading at $5.28.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences:

• 11^th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
  • 1x1 Meetings: August 10, 2026
  • Location: Virtual
    
    
• Canaccord Genuity 46^th Annual Growth Conference
• • Fireside Chat: August 11, 2026, at 11:30 AM ET
  • Location: Boston, MA

The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-302842362.html

SOURCE Lucid Diagnostics

FAQ

When will Lucid Diagnostics (NASDAQ: LUCD) present at the Needham Virtual MedTech & Diagnostics Conference in 2026?

Lucid Diagnostics plans to participate in 1x1 meetings at the 11th Annual Needham Virtual MedTech & Diagnostics Conference on August 10, 2026. According to Lucid Diagnostics, this event will be held virtually, enabling remote investor access.

What is the date and time of Lucid Diagnostics’ fireside chat at the Canaccord Genuity 46th Annual Growth Conference?

Lucid Diagnostics’ fireside chat at the Canaccord Genuity 46th Annual Growth Conference is scheduled for August 11, 2026 at 11:30 AM ET. According to Lucid Diagnostics, the event will take place in Boston, MA.

How can investors access the Lucid Diagnostics (LUCD) webcast from the Canaccord Genuity 2026 conference?

Investors can access the live and archived webcast of Lucid Diagnostics’ Canaccord Genuity fireside chat via the Investor Relations section of the Lucid Diagnostics website. According to Lucid Diagnostics, the webcast link will be available directly on its site.

How long will the replay of Lucid Diagnostics’ Canaccord Genuity 2026 fireside chat be available?

The replay of Lucid Diagnostics’ Canaccord Genuity fireside chat will be available for 30 days following the live broadcast. According to Lucid Diagnostics, investors can watch this replay through the company’s Investor Relations website section.

Is Lucid Diagnostics part of PAVmed (NASDAQ: PAVM) and does this affect the 2026 investor conferences?

Lucid Diagnostics is described as a subsidiary of PAVmed. According to Lucid Diagnostics, the announced 2026 investor conference participations involve Lucid’s management, with no additional structural or financial terms disclosed in this announcement.